September 2016 Issue of The Medicine Maker

Why is the pharma industry so despised when it has saved countless lives?

Not all successful biosimilar applications in Europe follow guidelines to the letter

With illegal drug use rising, can a cancer drug be repurposed to cure cocaine addiction?

Researchers say cancer should involve more frequent treatment at lower doses.

Our infographic looks at how the CPhI trade show has grown over the years.

Critics say a report from the UN on access to medicines ignores the real word industry

Richard Bergstrom has resigned from EFPIA - who will replace him?

Emma Walmsley is chosen as GlaxoSmithKline's new CEO.

Have Mylan been their own worst enemy with an imprudent pricing decision?

Costs of failing to communicate can cost you collaboration and investment.

David Banks offers a warning on using inappropriate lyophilization placebos.

Batch or continuous processing? For mAbs, a hybrid approach could be best.

It's Trump or Clinton for President. But what are the implications for pharma?

PhRMA explain why the US Elections are important for the pharma industry.

The original goal of 'Obamacare' was to increase access to health insurance, but has it worked?

Steve Keen talks to us about Trump, China, free trade and globalization

A new approach to outsourcing leverages external expertise and benefits internal learning.

Pauline Rudd explains why sugars and glycosylation are important for biosimilars.

Can hair follicles and nanotechnology help topical drugs overcome the skin barrier?

With an approaching patent cliff in biologics, are we be about to see a rise in litigation?

Sitting Down With… Akm Khairuzzaman, a 3D printing expert from the FDA.

Single-use technology could help pave the way towards continuous bioprocessing.

Will single use systems win out over stainless steel? Or is a hybrid approach best?

Robust formulation and coating expertise are required to get the best results with continuous coating.

Experts come together to discuss the chemistry of solubility and the drug delivery solutions of the future for dealing with poorly soluble compounds.

In this article, triple detection SEC and MDRS are considered within the context of characterizing complex drug formulations, with specific case studies and results illustrating their application.

In this article, we take an introductory look at how TDA works, the information it provides and its complementary application to other techniques within the drug development workflow. In addition, example case study data will showcase the performance of TDA relative to dynamic light scattering (DLS) for assessment of the impact of a range of parameters on the monomer-dimer-hexamer equilibrium of insulin.

This article explains how an inline probe was used to monitor a granulation at three different scales to confirm that, in each case, the granules produced were the same size, and more importantly produced tablets of identical quality as quantified by hardness.